Rhode Island’s Lifespan in talks for collaboration with Partners HealthCare, Care New England

The previously proposed merger between Boston’s Partners Healthcare and Care New England, one of the largest systems in Rhode Island, may have a third partner: Lifespan, the operator of Rhode Island Hospital.

The Providence Journal reports the three systems released a joint statement that they’ll enter into formal discussions about how they may collaborate “to strengthen patient care delivery in Rhode Island.” While the idea of Partners taking over a Rhode Island system has led to pushback from local entities—including an unsolicited offer from Brown University to acquire Care New England—Lifespan CEO Timothy Babineau, MD, said he was excited about what the partnership could do for care delivery in the region.

“Lifespan has always been interested in partnering with like-minded, superb organizations, and I look forward to the discussions and the potential to continually improve the seamless and coordinated care we deliver to our patients,” he said in a separate statement to the Journal.

What the partnership could be is an open question, as the joint statement didn’t mention the word “merger.” But that’s exactly what seems to be on the table, in the opinion of United Nurses and Allied Professionals spokesman Ray Sullivan.

“We are curious to see what develops from talks between Lifespan, Partners HealthCare and Care New England,” Sullivan said. “Should a three-way deal be consummated, we would expect to begin discussions with management on how to strengthen resources for bedside caregivers and support staff as part of a wider effort to improve healthcare delivery in Rhode Island.”

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.